Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Drugs for Otolaryngology (Ear, Nose, Throat) in Phase I Clinical Development in UNITED STATES

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Decibel Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Decibel Therapeutics Publishes Results from Early-Stage Study of Therapy Designed to Prevent Hearing Loss

              Contact the Supplier

              Lead Product(s): Sodium Thiosulfate

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 26, 2020

              Details:

              The Phase 1a trial showed that DB-020 was safe and well-tolerated in healthy volunteers and confirmed that administration of DB-020.

              Decibel Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Decibel Therapeutics to Present at the 43rd Annual Association for Research in Otolaryngology (ARO) Conference

              Contact the Supplier

              Lead Product(s): DB-020

              Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 24, 2020

              Details:

              These developments demonstrate the strength of Decibel's unique approach and will continue to enable our efforts in restoration and regenerative medicine approaches to the inner ear.

              PharmaCompass__DigitalAd